Oura, the Finnish-founded maker of the smart ring that tracks sleep, temperature, and heart rate, filed paperwork on September 4, 2026 to go public, targeting a valuation north of $16 billion and seeking to raise as much as $3 billion in the offering. The filing, reported by American Bazaar Online and confirmed across health-tech trade press, positions Oura’s enormous physiological dataset — and the AI models trained on it — as the centerpiece of its pitch to public-market investors.
The filing caps a remarkable run for a company that started as a niche wellness accessory. Oura’s ring competed for years against bigger, better-funded wearable makers with a single differentiator: a design small enough to wear all day and all night, which let it capture sleep data that wrist-based devices historically struggled to gather comfortably. That data advantage is now the core of its public-offering narrative.
Revenue Nearly Doubling Year Over Year
Oura’s financials show the scale of its growth: the company brought in roughly $500 million in 2024, about $1 billion in 2025, and expects close to $2 billion in 2026. For the nine-month period ending June 30, revenue jumped from $697 million to $1.2 billion year over year. Oura has sold 3.6 million rings to date and counts around 5 million paid subscribers, with an 85 percent weighted-average 12-month membership retention rate — a figure the company is expected to lean on to argue its subscription model, not just ring sales, drives durable revenue.
A Dataset of 42 Billion Hours Powering the AI
Central to Oura’s pitch is what the company describes as nearly 42 billion hours of physiological data spanning more than 50 health and wellness metrics, which it says powers the machine-learning models behind features like Oura Advisor and the newer women’s health AI model launched in March 2026 that adds cycle prediction, fertility window estimation, and pregnancy monitoring using the ring’s temperature sensors. Oura Labs, the company’s experimental feature arm, also introduced Health Radar, which continuously monitors biometric signals for patterns that may warrant attention, including signs related to blood pressure and nighttime breathing.
Ring 5 and a New Virtual Care Layer
The IPO filing follows the May 2026 launch of Oura Ring 5, marketed as the company’s smallest smart ring yet, shrinking the wearable’s design by roughly 40 percent while adding predictive health features. Oura Ring 5 also introduced an AI-enabled care layer inside the Oura app, giving members access to licensed physicians through Counsel Health, a virtual-care practice built around message-based consultations — echoing the clinician-access push other wearable makers have made this year.
The virtual-care layer mirrors a broader pattern among wearable makers in 2026: rather than compete purely on sensor accuracy, companies are racing to bundle clinical-adjacent services directly into their subscription apps, on the theory that access to a physician or coach, however limited, makes the monthly membership fee easier to justify than a one-time hardware purchase.
A Lawsuit Casts Doubt on the Sleep-Stage Claims
Oura’s IPO ambitions come with an unresolved legal cloud: a proposed class-action lawsuit alleges the rings cannot accurately detect sleep stages and instead rely on unreliable AI estimates, a claim that goes to the heart of the company’s marketing around precision sleep tracking. Sleep researchers have separately cautioned for years that consumer sleep trackers, however sophisticated their AI, are validated against polysomnography with varying degrees of agreement, and that positioning any wearable’s output as clinical-grade risks overstating what the device can actually measure.
Celebrities, Competition, and a Crowded IPO Window
Oura’s ambassador roster, which includes Jennifer Aniston, Prince Harry, and Tom Holland, has helped keep the $350-to-$400 ring a fixture in wellness culture since the Finland-based company was founded in 2013. But it now goes public into a field crowded with Whoop’s subscription-only clinician access, Apple’s newly announced Health Sensing System in the Apple Watch Series 12, and a wave of AI-driven sleep and nutrition apps all competing for the same wellness-conscious, data-hungry consumer.
What’s Next
If the offering proceeds near its targeted valuation, Oura would become one of the largest pure-play wearable IPOs to date, testing whether public investors will pay a premium for a dataset-and-AI story rather than hardware margins alone. The outcome of the sleep-stage-accuracy lawsuit, along with how regulators eventually treat AI-generated health guidance from consumer wearables, could shape how much scrutiny Oura and its rivals face once they answer to public shareholders rather than just app-store reviewers.
Investors weighing the offering will also have to judge how durable Oura’s 85 percent retention rate is against a market where Apple and Whoop are both racing to close the same sleep-and-recovery feature gap, and where a single adverse court ruling on the sleep-stage lawsuit could force costly changes to how the company markets its core product.
Photo: Brett Jordan / PEXELS via Pexels
